Tazbentetol for schizophrenia shows symptom improvement in phase 2 trial. Tazbentetol likely modulates fascin-1/F-actin dynamics, thereby promoting synaptic regeneration in the brain.

Interim analysis (n=16) showed larger PANSS reductions with tazbentetol than placebo (−11.1 vs −5.5), suggesting activity across positive and negative symptom domains. Tazbentetol is a first-in-class investigational synaptic regenerative therapy. The drug is designed to trigger neurons to produce new synapses, restoring cognitive, motor, and other functions. This medication promotes formation of dendritic spines which have glutamatergic synapses, intending to reduce symptoms of schizophrenia.